FDA Greenlights Axsome’s Alzheimer’s Agitation Therapy
FDA Approval Marks First Treatment for Alzheimer’s Agitation
The U.S. Food and Drug Administration has approved Axsome Therapeutics’ drug for agitation associated with Alzheimer’s disease, a breakthrough for millions of patients and caregivers. The decision, announced late Tuesday, comes after decades without a specific therapy for this debilitating symptom.
“This is a historic moment—clinicians finally have a targeted option,” said Dr. Emily Hartfield, a geriatric psychiatrist at Johns Hopkins University. “Agitation in Alzheimer’s often leads to hospitalization and caregiver burnout, and now we can address it directly.”
How the Drug Works
The therapy, known under the brand name Symbravo (dextromethorphan/bupropion), targets two brain pathways involved in mood and impulse control. Clinical trials showed a significant reduction in agitation episodes compared to placebo, with manageable side effects like dizziness and nausea.
Axsome CEO Dr. Lara Chen called the approval “a testament to our commitment to neuropsychiatric innovation.” The company plans to launch the drug within the next 60 days.
Background: The Agitation Crisis in Alzheimer’s
Alzheimer’s disease affects nearly 6 million Americans, with agitation—ranging from pacing to verbal aggression—occurring in up to 70% of patients. Until now, clinicians could only prescribe off-label antipsychotics, which carry black-box warnings for increased stroke risk in elderly dementia patients.
The FDA’s decision comes amid a broader push for centralized oversight of biologics: Katherine Szarama has been named acting head of CBER as the agency searches for a permanent leader. Meanwhile, patient advocacy groups have long pressed for safer agitation therapies.
What This Means for Patients and the Field
For families, the approval offers a new tool to reduce distress and improve quality of life. “This isn’t a cure, but it can transform daily care,” noted Dr. Mark Rivera, a neurologist at the Cleveland Clinic. The market impact is also significant: analysts project peak sales exceeding $2 billion annually.
Still, experts caution that the drug is not for everyone. “Patients with a history of seizures or eating disorders should not take it,” Hartfield said. Axsome must also conduct post-marketing studies to monitor long-term safety.
In related biotech news, Julia Vitarello is launching a new effort to scale bespoke medicines after her first startup faltered, and Matt Herper reflects on the legacy of genomics pioneer J. Craig Venter.
CBER Leadership Transition
The FDA named Katherine Szarama as acting head of its Center for Biologics Evaluation and Research (CBER) this week. Szarama, a veteran regulator, will oversee gene therapies and vaccines while the search for a permanent director continues. This move could affect timelines for other Alzheimer’s therapies under review.
Bespoke Medicine Scale-Up
Julia Vitarello is launching a new initiative to manufacture personalized genetic therapies for rare diseases. Her previous startup, Mila’s Miracle Foundation, struggled with scalability. The new project aims to cross that chasm using modular production platforms.
Genomics Pioneer Remembered
Matt Herper’s recent retrospective on J. Craig Vener’s career highlights how the scientist’s early vision—sequencing the human genome for under $1,000—paved the way for today’s CRISPR and RNA therapies. Though controversial, Venter’s influence remains embedded in modern biotech.
—Reporting by STAT’s biotech team